Back to top

Analyst Blog

Impax Laboratories, Inc. (IPXL - Snapshot Report) announced that it has acquired two generic products from Actavis plc (ACT - Analyst Report) for a cash consideration.

The financial terms of the agreement were not disclosed.

As per the agreement, Impax will acquire Ursodiol tablet and Lamotrigine orally disintegrating tablet. We note that the Abbreviated New Drug Application (ANDA) for Lamotrigine has been approved but the product is not marketed yet.

The acquisition will broaden Impax’s generics’ portfolio which includes generic Adderall XR, fenofibrate (generic to Lofibra) and oxymorphone HCI ER.

We note that Impax has been working actively on strengthening its generic products portfolio in recent times. In Apr 2014, Impax had launched the authorized generic version of Sanofi’s (SNY - Analyst Report) Renvela, which will significantly boost the top line in 2014. Moreover, Impax is seeking approval for its pending ANDA for generic Renvela with the FDA.

Meanwhile, Impax is looking to get its late-stage candidate, Rytary, approved for the symptomatic treatment of Parkinson’s disease. The FDA accepted Impax’s re-submission of New Drug Application (NDA) for Rytary in Apr 2014.

The FDA will inspect the manufacturing facilities involved in the production of Rytary. A response from the agency should be out by Oct 9, 2014. Impax also intends to file for EU approval for Rytary in the second half of 2014.

Impax currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the healthcare sector might consider Mallinckrodt plc (MNK - Snapshot Report), which carries a Zacks Rank #2 (Buy).

 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 115.36 +6.79%
US SILICA H… SLCA 70.48 +3.65%
TRIQUINT SE… TQNT 19.49 +2.63%
RF MICRO DE… RFMD 11.78 +2.48%
CHYRONHEGO… CHYR 2.63 +2.33%